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Abstract Myostatin is an extracellular cytokine mostly
expressed in skeletal muscles and known to play a crucial
role in the negative regulation of muscle mass. Upon the
binding to activin type IIB receptor, myostatin can initiate
several different signalling cascades resulting in the
upregulation of the atrogenes and downregulation of the
important for myogenesis genes. Muscle size is regulated
via a complex interplay of myostatin signalling with the
insulin-like growth factor 1/phosphatidylinositol 3-kinase/
Akt pathway responsible for increase in protein synthesis in
muscle. Therefore, the regulation of muscle weight is a
process in which myostatin plays a central role but the
mechanism of its action and signalling cascades are not
fully understood. Myostatin upregulation was observed in
the pathogenesis of muscle wasting during cachexia
associated with different diseases (i.e. cancer, heart failure,
HIV). Characterisation of myostatin signalling is therefore a
perspective direction in the treatment development for
cachexia. The current review covers the present knowledge
about myostatin signalling pathways leading to muscle
wasting and the state of therapy approaches via the
regulation of myostatin and/or its downstream targets in
cachexia.
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1 Introduction
Cachexia is a syndrome occurring at terminal stages of
diseases such as cancer, chronic heart failure, chronic
kidney failure or AIDS [1]. This syndrome is characterized
by loss of body weight as a consequence of pathological
changes in different metabolic pathways. It leads to
increased morbidity and mortality irrespective of the
underlying disease. A major role in the development of
cachexia is played by the loss of muscle mass accompanied
by the loss of fat [2]. Such muscle hypotrophy is the result
of multiple alterations at the molecular level, e.g. the
disturbance in the balance between protein degradation and
protein synthesis [1]. Proinflammatory cytokines such as
interleukin-1, interleukin-6 and tumour necrosis factor-α
(TNFα) were shown to play an important role in the
development of muscle wasting [3]. However, there is no
established treatment for cachexia based on the regulation
of their signalling. Many different peptides have received
therapeutic interest over the last decade, including ghrelin,
leptin, melanocortins and growth hormone [4–6]. In 1997,
the role of another extracellular factor in the negative
regulation of muscle mass, referred to as myostatin, was
discovered [7]. Myostatin upregulation was found in the
pathogenesis of cancer, HIV, heart failure associated
cachexia and aging [8–12]. It has become one of the main
targets in the investigation of the regulation of muscle mass.
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Myostatin, also known as growth/differentiation factor-
8 (GDF-8) is a member of tumour growth factor β (TGF-
β) family [7]. This protein is a homodimer with a molecular
weight of 25 kDa and a disulfide bond between the
monomers at the C-terminal regions [7]. Myostatin circu-
lates in the blood in a latent form with an additional non-
covalently bound propeptide at the N-terminus. Proteolytic
cleavage of the propeptide by the bone morphogenetic
protein (BMP)-1/tolloid family of metalloproteinases is
necessary for activation of protein function [13].
The role of myostatin in skeletal muscle was discovered
using the method of gene disruption in mice. Mstn null
animals showed significant increase in muscle mass (up to
two-fold) and decrease of fat tissue compared to the wild
type [14, 15]. Similar effects were observed in the presence
of natural mutations of Mstn in cattle, sheep, dogs and
humans [16–19] and upon the inhibition of the protein
function in adult mice [20]. At the same time, over-
expression of Mstn led to the reduction of muscle mass
suggesting myostatin to be a negative regulator of skeletal
muscle growth. During embryogenesis, myostatin is exclu-
sively expressed in skeletal muscle [7] to control the
differentiation and proliferation of the myoblast, but in
adulthood, it is not only restricted to skeletal muscle but
also detected in other tissues (e.g. heart, adipose tissue,
mammary gland) [7, 21–25].
The expression of myostatin in the healthy heart is low
and mostly detected in Purkinje fibres but not in cardio-
myocytes [22]. After myocardial infarction, increased
expression of myostatin was observed in sheep, but its
expression was restricted to the damaged zone [22].
Moreover, George et al. recently published new data
suggesting the increase of myostatin levels in the failing
heart [26]. The authors also showed an increase of its latent
complex in circulation and expression of BMP-1 that could
explain the development of cachexia in patients with heart
failure [26]. These data are in accordance with the recent
research of Heineke et al. who suggested that myostatin
produced by cardiomyocytes could stimulate muscle wast-
ing in heart failure [27].
The role of myostatin in the regulation of adipose tissue
is not well understood. Myostatin and its receptor (type IIB
activin receptor, ActRIIB) were shown to be expressed in
adipose tissue at low levels [7, 14]. Several studies showed
the negative effect of myostatin on preadipocyte differen-
tiation and proliferation [28, 29]. Contrary, an effect of
promotion of the differentiation leading to the increased
adipogenesis was observed in pluripotent mesenchymal
cells [30, 31]. Moreover, Mstn null mice had a decreased
amount of adipose tissue [14, 32]. It is still unclear whether
the effect of myostatin on adipose tissue is the direct result
of regulation or it is an indirect consequence of skeletal
muscle growth. Reduced adiposity was observed in
different transgenic mouse models of muscle hypertrophy
[33–35]. Thereby the decreased amount of adipose tissue in
Mstn null mice could be an indirect drawback of significant
increases in muscle mass. Such an effect can be mediated
through leptin—adipose-specific hormone regulating food
intake and energy homeostasis. Its level was shown to be
lower in Mstn null mice [32]. Therefore, additional experi-
ments are required to determine the role of myostatin in
adipose tissue.
3 Binding to the cell
Myostatin is an extracellular cytokine, and as many other
members of the TGF-β family, it mediates the signal
through activin receptors [36]. Active myostatin mostly
binds to the ActRIIB [36] and engages the signalling
cascade leading to the inhibition of myoblast differentiation
and proliferation (Fig. 1). ActRIIB can mediate other
signalling pathways with diverse affinity for ligands—high
for activin A and GDF11, low for BMP-2 and BMP-7 [38].
These ligands are responsible for several cell responses by
activating different members of the Smad family of
transcription factors.
Activin receptors are transmembrane threonine/serine
kinases divided in two types. Type I receptor (ALK 4 and
ALK 5 for myostatin [28]) has the unique GS domain
located closely to the intracellular space and adjacent to the
kinase domain which is absent in the second type (ActRII).
Binding of myostatin with ActRIIB causes its assembly
with type I receptor and phosphorylation of its GS domain.
Therefore, the signal of myostatin is mediated through
activated complex of two receptors [39].
Myostatin signalling through ActRIIB is crucial for the
regulation of muscle growth. The natural defect in ActRIIB
sensitivity in humans leads to a significant increase in
muscle mass [40]. The same effect was observed in the
experiments that used blockade of the murine receptor [40].
In the characterization of the ActRIIB role in myostatin
signalling, the soluble form of this receptor (sActRIIB) is
used. sActRIIB is a fusion protein of the receptor
extracellular domain with immunoglobulin Fc. It acts as a
decoy receptor for myostatin. Healthy mice treated with
sActRIIB showed a 60% increase in muscle mass, just
2 weeks after treatment initiation [40]. Surprisingly, in mice
treated with antimyostatin antibodies (JA-16) or myostatin
propeptide known to bind circulating myostatin, the
hypertrophy of muscle was lower compared to sActRIIB
[41, 42]. Moreover, in Mstn knockout mice treated with the
sActRIIB, an increase in muscle mass by 15–25% was
observed [40]. This suggests the presence of at least one
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mass of skeletal muscle. Souza et al. proposed that such
ligands could embrace BMP-11, activin A, B and AB, but
this hypothesis requires more evidence [43]. However, it
could explain why myostatin blockade in clinical trials had
no significant effect on muscle weight [44]. The results
obtained in cancer models of Lewis lung carcinoma and
B16F10 melanoma are in agreement with this theory. It was
shown that myostatin knockout mice had a more pro-
nounced tendency to develop muscle wasting than wild-
type animals. This finding suggests that myostatin is not the
only ligand providing the signal leading to muscle wasting.
On the other hand, the same study showed that myostatin
could prevent muscle wasting to a certain degree [45].
Recently, Zhou et al. moved a significant step forward in
development of a novel therapy [46]. The authors demon-
strated that sActRIIB prevents or even reverses develop-
ment of cancer cachexia. Their research showed the
connection between the development of cancer cachexia
and the activation of activin receptor. Blockade of ActRIIB
led to the regeneration of muscle and cardiac mass [46].
These data suggest a fundamental role of ActRIIB-mediated
signalling pathways in the induction of muscle wasting
during cachexia and can be used in the development of
treatments against cachexia.
4 Myostatin extracellular regulation
Myostatin circulates in the blood in a latent complex with
non-covalently bound propeptide at the N-terminus [13, 36,
47], crucial for the correct folding of the protein [20]. The
propeptide was shown to bind the active myostatin in vivo
and in vitro, and its overexpression in mice results in an
increase of muscle mass [36, 48].
Specific inhibitors can prevent binding of myostatin to
ActRIIB in serum. One of them is follistatin, an extracel-
lular cysteine-rich glycoprotein with a structure not similar
to members of TGF-β family. Follistatin binds myostatin
and inhibits its activity by preventing its binding to the
receptor [11, 36]. Overexpression of follistatin in vivo leads
to muscle hypertrophy similar to the one observed in Mstn
null mice [36]. Mice with homozygous mutation in the Fst
gene showed a decrease in muscle mass suggesting an
important role of follistatin in the regulation of myogenesis
[49]. Follistatin-like 3 protein has more than 30% homol-
ogy with follistatin and was also shown to bind circulating
myostatin [41].
Another inhibitor of myostatin is growth and differenti-
ation factor-associated serum protein 1 (GASP-1). Unlike
members of the follistatin family, GASP-1 does not have
affinity to activin [42]. The structure of GASP-1 is different
from previously described inhibitors: With the exception of
one follistatin domain, it has additional domains typical for
protease inhibitors. Interestingly, GASP-1 can also bind to
the myostatin propeptide and possibly regulate the activa-
tion of myostatin through proteolytic cleavage [42].
Moreover, myostatin can be inactivated upon covalent
binding to latent TGF-β binding protein 3 (LTBP3). This
inactive complex of myostatin/LTBP3 is used for myostatin
storage in the extracellular matrix [50]. Taken together,
myostatin is regulated by at least four different inhibitors
via binding of the active or latent form. The mechanisms of
myostatin inhibition still remain elusive, and the crosstalk
between the different intrinsic inhibitors is still unclear. The
variety of inhibitors emphasizes the importance of a strict
myostatin regulation in order to avoid muscle damage and
wasting. The schematic mechanism of myostatin extracel-
lular signalling is presented in Fig. 1.
5 Intracellular response
Skeletal muscle mass is maintained as a consequence of
two main molecular mechanisms: protein synthesis and
protein degradation. Despite the profound knowledge of the
Fig. 1 Myostatin pathway.
Myostatin is synthesized and
secreted by muscle cell; it sig-
nals through the activin IIB/
ALK 4/5 heterodimer to activate
different pathways resulting in
the decrease in muscle growth
and differentiation (with per-
mission from [37])
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details of the molecular mechanisms of its action are poorly
understood. It has been suggested that binding of myostatin
to the ActRIIB results in the phosphorylation of two serine
residues of Smad2 or Smad3 at COOH domains. This leads
to the assembly of Smad2/3 with Smad4 to the heterodimer
that is able to translocate to the nucleus and activate
transcription of target genes [51–53]. One of the known
downstream targets of Smad signalling is MyoD, a
transcriptional factor that is involved in skeletal muscle
development and takes part in the repair of damaged
skeletal muscle [54–57]. Downregulation of myoD expres-
sion was shown in vitro and in vivo during cachexia,
possibly via TNFα through the induction of the NF-κB
pathway. Interestingly, myostatin downregulates myoD in
an NF-κB-independent way [58, 59]. Myostatin also
inhibits Pax3 expression, which is possibly an upstream
target of MyoD [58, 60, 61]. Moreover, Smad signalling
targets other genes such as myf5 and myogenin, known to
be important for myogenesis [62].
Interestingly, other Smad proteins (Smad6 and Smad7)
work as agonists. They compete for the binding to the
activin type I receptor and thereby inhibit signalling of
TGF-β family members [63, 64]. Myostatin was also
shown to activate Smad7 transcription. Smad7, in turn, is
able to inhibit the association of Smad2/3 with Smad4 [65,
66]. Therefore, the Smad pathway is regulated by feedback
control [67].
Myostatin signalling via Smad has been intensively
investigated, but it is not the only feasible signalling
pathway. TGF-β family members were shown to activate
mitogen-activated protein kinases (MAPKs), particularly
p38 and extracellular signal-regulated kinase 1/2 (ERK1/2)
[68–71]. p38 MAPK is responsible for the cell response to
stress factors and was shown to be activated by myostatin
via TGF-β activated kinase 1 (TAK-1)/MAPK kinase
(MAPKK) cascade. Its signalling results in the down-
regulation of myogenesis-related genes, but it does not
target Smads [72]. The role of ERK1/2 in the regulation of
muscle mass is controversial. On the one hand, there are
studies confirming that ERK1/2 takes part in the process of
satellite cell proliferation that is necessary for the mainte-
nance of skeletal muscle weight [73] and induces protein
synthesis under physiological conditions [74, 75]. On the
other hand, there are experiments showing an opposite
effect of ERK1/2 activation [76–79]. Thus, the data suggest
that increased activity of ERK1/2 leads to the differentia-
tion inhibition in several cell types [76, 77]. At the same
time, myostatin significantly activated ERK1/2 in C2C12
cells. Similar effects were observed in mice during
systematic administration of myostatin [78]. Taken together,
it seems likely that myostatin mediates its signal at least
partially through ERK1/2 activation. Therefore, different
responses through ERK1/2 could be caused by different
levels of myostatin corresponding to normal and patholog-
ical conditions. MAPK cascade normally involves the
activation of Ras/Raf/MEK1. To check whether myostatin
uses the same pathways to activate ERK1/2, some experi-
ments were done. Using an inhibitor of MEK1 in C2C12
cells, Yang et al. showed that this kinase is involved in the
myostatin-induced activation of ERK1/2 [78]. Moreover,
such inhibition of MEK1 leads to the rescue of cell
differentiation, which means that MEK-1/ERK1/2 play a
role in differentiation suppression by myostatin. The
presence of dominant negative form of Ras was shown to
positively influence MEK1/ERK1/2 through the down-
stream activation of Raf. Therefore, myostatin activates
ERK1/2 via Ras/Raf/MEK1 pathway [78].
6 Cross talk of myostatin and IGF-1
One of the main positive regulators of muscle growth is
insulin-like growth factor 1 (IGF-1). Under normal con-
ditions, IGF-1 signalling seems to be dominant and blocks
the myostatin pathway [80]. However, an inhibition of IGF-
1 was observed when myostatin is overexpressed [81, 82].
IGF-1 can prevent TGF-β family-mediated apoptosis [83],
and it was shown that in the absence of IGF-1, the level of
apoptosis in C2C12 cells treated with myostatin increased.
Yang et al. speculate it may in part explain the ability of
myostatin in regulating cell cycle but not apoptosis in
normal conditions [84].
The mechanism by which IGF-1 regulates myostatin
signalling includes the inhibition of transcription factors
responsible for the induction of atrogenes via phosphory-
lation with phosphatidylinositol 3-kinase (PI3K)/Akt path-
way. Akt plays a significant role in different metabolic
processes in the cell, particularly in the hypertrophic
response to insulin and IGF-1 [85, 86]. Akt is the crossing
point between IGF-1/myostatin pathways. The results of
several studies suggest that the genetic loss of myostatin
leads to the increase in Akt activity in skeletal muscle in
vivo and in vitro [82, 87]. In contrast, a decreased level of
phosphorylated Akt is associated with incubation of
myotubes with myostatin [58]. It is likely that in the
conditions of muscle wasting, myostatin can switch Akt/
mammalian target of rapamycin (mTOR) pathway, respon-
sible for protein synthesis, to inhibition of protein synthesis
involving FoxO, GSK-3β or other unknown patterns
leading to the loss of muscle mass. These pathways will
be discussed below in more detail.
Akt/FoxO The class of Forkhead box O (FoxO) transcrip-
tion factors is involved in the regulation of energy
metabolism. FoxOs take part in the formation of skeletal
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distribution [88, 89]. During myoblast proliferation, FoxO1
and FoxO3 are localized in the cytoplasm in the latent,
phosphorylated form. Upon initiation of differentiation,
FoxO translocates to the nucleus where it binds to DNA
and regulates transcription. Akt regulates the activity of
FoxO1 and FoxO3 by phosphorylating them and thereby
retaining them in the cytoplasm [58]. In myotube culture,
the level of FoxO1 in the nucleus was shown to increase
after treatment with myostatin [58, 90], together with
FoxO3 resulting in the induction of the muscle-specific
E3-ubiquitin ligases atrogin-1 (MAFbx) and MuRF-1 [91,
92]. Expression of constitutively active FoxO1 in transgenic
mice led to decrease in myoblast differentiation and a
reduction in muscle weight [93]. In muscle, FoxOs are
known to interact with Smad3 and Smad4 inducing the
protein degradation. Recently, it was shown that FoxO1 and
Smad synergistically increase the expression of myostatin
mRNA and its promoter activity in C2C12 myotubes but via
different pathways [94]. Taken together, myostatin-mediated
signalling activates FoxO, and it leads to the upregulation of
proteasome ubiquitin ligases MuRF-1 and atrogin-1, which
participate in protein degradation.
Akt/GSK-3β Cycline D1 is an important component for G1
phase of cell cycle which is also regulated via PI3K/Akt
pathway. In C2C12 myoblasts treated with myostatin during
the phase of active cell growth, a decrease in cycline D1
levels was shown, suggesting that myostatin targets cycline
D1 for proliferation inhibition. In favour of this hypothesis,
overexpression of cycline D1 was shown to rescue cell
cycle. The activation of GSK-3β via dephosphorylation at
Ser 9 increases proteolysis of cyclin D1 [95] in the response
to myostatin-mediated dephosphorylation of Akt at Ser 473.
Usage of IGF-1 or active Akt treatment blocks myostatin
induced arrest of cell proliferation [84]. Thus, one more
pathway activated by myostatin suggests that inhibition of
Akt plays a dramatic role in the providing of myostatin
signalling.
Akt/mTOR/p70s6K This pathway is important for the
differentiation of myoblasts and hypertrophy of myotubes.
mTOR is a kinase downstream of Akt, which phosphor-
ylates 4E-BP1 and p70s6k thereby inducing initiation of
protein synthesis [85, 96]. In Mstn knockout mice, an
increase in Akt/mTOR/p70s6K signalling was observed
[87]. There are two mTOR complexes called TORC1 and
TORC2, containing the proteins RAPTOR and RICTOR,
respectively [97]. Activation of TORC1 leads to protein
synthesis, while TORC2 plays a significant role in the
feedback Akt phosphorylation leading to the blockade of
FoxO signalling [98]. Inhibition of RAPTOR was shown to
play an important role in myostatin signalling, whereas
RICTOR is necessary for the cell differentiation itself.
Inhibition of RAPTOR amplifies myostatin actions such as
Smad phosphorylation [80].
Additional data confirming the connection between
myostatin and Akt pathways were received in experiments
with hypoxic muscles. The expression of myostatin was
shown to be upregulated under these conditions [99]. At the
same time, the Akt/mTOR pathway was downregulated in
the rats with chronic hypoxia [100].
In conclusion, signal transduction of myostatin is a
complex process involving activation and inhibition of
several cellular signalling pathways. These pathways result
in the downregulation of the expression of myogenic
factors, decrease in protein synthesis and activation of
proteasome–ubiquitin ligases. The schematic picture of
myostatin signalling is presented in Fig. 2. There are a lot
of questions still connected with the order of activation and
precise importance of each pathway and its contribution in
the development of muscle wasting.
7 Treatment
Myostatin has become a main target for the development
of drugs for cachexia and muscle wasting diseases.
Despite the experiments using antimyostatin substances
that were conducted, there are no drug discoveries
against muscle wasting in cachexia so far. The informa-
tion about compounds that were involved in clinical trials
is scarce, but none of the known substances had a
positive effect. MYO-029 is recombinant human
myostatin-specific antibody that did not show a signifi-
cant improvement in muscle strength and function in
adult muscular dystrophies [44]. The other compound
developed by Amgen, AMG 745, has an unknown
composition, but its testing was stopped after phase I
clinical trials [102]. The problem of using antimyostatin
compounds is likely due to the ability of the ActRIIB to
bind other ligands from the TGF-β family resulting in a
redundancy of myostatin.
The impact of sActRIIB use in the regulation of
muscle mass is intensively studied at the moment.
Recently, very positive results were published by Zhou
et al. [46]i nC - 2 6t u m o u r - b e a r i n gm i c e ,w h e r et h eu s eo f
sActRIIB resulted in the prolongation of life and reversal
of muscle wasting during cachexia. In this study, a positive
effect on cardiac muscle was also seen. The results of this
study provide a major step forward in establishing novel
cachexia therapies.
The significance of these results for the treatment of
cardiac cachexia was shown by Heineke et al. [27], who
observed that myostatin produced from cardiomyocytes is
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myostatin subsequently activated muscle wasting. The
deletion of Mstn from cardiomyocytes and inhibition of
myostatin protein using antibodies in mice prevented
muscle wasting in heart failure [27].
8 Conclusion
Myostatin is a negative regulator of myoblast proliferation
and differentiation. Normally it functions to regulate
hypertrophy of muscles, but a role in the induction of
muscle loss was observed in muscle wasting diseases and
cachexia associated with severe illnesses. The mechanism
of myostatin signalling is complex and involves the
activation of several downstream pathways. Additional
studies are required to elucidate the cross talk between the
signalling cascades and their regulation. The experiments
with myostatin propeptide and antimyostatin antibodies
showed a positive effect on regulation of muscle mass in
different models of wasting but lacked efficacy in phase I
clinical trials. The most promising target in terms of
cachexia treatment seems to be the activin type II receptor.
The blockade of this receptor led to a significant increase in
muscle mass and even its restoration in cancer cachexia.
Therefore, targeting myostatin and its receptor represent a
Fig. 2 Different pathways of myostatin signalling. → The activation
of the process, -| the inhibition of the process, ––the presence of
intermediate steps either unknown or omitted in the figure. 1
Canonical pathway of Smad activation. Myostatin binds to ActRIIB
and induces its assembly with activin type I receptor. Subsequent
phosphorylation of Smad2/3 leads to its binding with Smad4 and
translocation of the complex to the nucleus where it blocks the
transcription of genes responsible for the myogenesis. Smad6 and
Smad7 compete for the binding with activin type I receptor. Smad7
can also prevent the formation of the Smad 2/3 and Smad4 complex. 2
MAPK activation. The activation of MAPKs is mediated via
myostatin using different pathways: TAK-1/MAPKK for p38 MAPK
or Ras/Raf/MEK1 for ERK1/2. It leads to the blockade of genes
responsible for myogenesis. 3 Inhibition of Akt signalling. Akt
phosphorylation occurs in the response to insulin and IGF-1. In
normal case, active Akt induces mTOR signal leading to the protein
synthesis; at the same time, it inhibits FoxO by phosphorylation. In
the pathological conditions, dephosphorylated Akt does not inhibit
FoxO. It leads to the accumulation of FoxO in the nucleus where it
binds to the DNA and induces the transcription of E3 ubiquitin ligases
MURF-1 and Atrogin-1. Smad3 and Smad4 possibly participate in
FoxO signalling (adapted from [51, 84, 90, 101])
148 J Cachexia Sarcopenia Muscle (2011) 2:143–151promising direction in the development of effective treat-
ments for cachexia and muscle wasting diseases.
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